The Women's Cancer Program (WCP) is a highly interactive, multidisciplinary research program co-led by Drs. Goetz, Degnim, and Bakkum-Gamez and composed of 61 basic and population scientists and clinical investigators from 14 departments and centers at Mayo Clinic in Rochester, MN; Arizona; and Florida. Its overarching goal is to advance the understanding of, and management strategies for, breast and gynecologic cancers. The substantial intraprogrammatic interactions reflect multidisciplinary WCP teams that focus on 4 major Specific Aims: 1) Genomics: to determine both host and tumor genetic alterations; 2) Biology: to define key mediators and pathways in the biology of women's cancers; 3) Advances in risk assessment: to define subgroups of women at increased risk; and 4) New clinical strategies: to develop and test innovative clinical strategies, especially based on discoveries from Specific Aims 1-3. The WCP's solid scientific base and opportunities for interactions have resulted in the renewal of the Mayo Clinic Breast and Ovarian SPOREs and new Stand Up to Cancer, DoD, and multiple R01 grants during the current project period. All of these grants support investigator-initiated clinical trials at Mayo Clinic and within clinical trial networks, including the Alliance for Clinical Trials, the Translational Breast Cancer Research Consortium, and the Stand Up to Cancer collaboration, with broad participation by Program members. Total direct peer-reviewed grant funding within the Program is $5.3M, with 56% from NCI. The Program has an additional $14.4M in direct, non-peer-reviewed funding. Since 2013, Program members have contributed 978 publications to the literature; 49% represent intraprogrammatic work, 29% reflect interprogrammatic collaborations, and 158 (16%) are in journals with an impact factor ?10. Some of this work has changed clinical practice, including reclassification of BRCA2 variants of unknown significance; development and implementation of a new breast cancer risk model; co-development of rucaparib, resulting in FDA approval and extension of PARP inhibitors beyond high-grade serous ovarian cancers with germline BRCA1 or BRCA2 mutations; and the development of Clinical Pharmacogenetics Implementation Consortium (CPIC) practice guidelines regarding the use of CYP2D6 genotype to guide tamoxifen treatment. WCP members benefit from the use of numerous Shared Resources, especially Biospecimens Accessioning and Processing, Pathology Research, Biostatistics, Survey Research, and the MCCC Clinical Research Office. To catalyze new and maintain ongoing collaborations, the Program has monthly scientific symposia and Breast and Gynecologic Cancer Disease Group meetings, weekly multidisciplinary conferences for breast and gynecologic cancer researchers, quarterly combined breast and gynecologic cancer conferences, and yearly multidisciplinary breast CME courses that rotate among the 3 Mayo sites. There is significant institutional and Cancer Center support for women's cancer?related research, education, outreach, and clinical practice endeavors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-45
Application #
9703022
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153

Showing the most recent 10 out of 1129 publications